Minimal-medication approaches to treating schizophrenia

Advances in Psychiatric Treatment

Volumn 15, Issue 3, 2009, Pages 209-217

  Calton, Tim ^a,b   Spandler, Helen ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b INSTITUTE OF MENTAL HEALTH   (United Kingdom)

^c UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; COMMUNITY CARE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; MEDICAL LITERATURE; PRACTICE GUIDELINE; PSYCHOPATHY; PSYCHOSIS; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SELF HELP; SOCIAL ADAPTATION; SOCIAL INTERACTION;

EID: 68949203717     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.bp.107.004028     Document Type: Article

References (82)

1. Aderhold V, Statsny P, Lehmann P (2007) Soteria. An alternative mental health reform movement. In Alternatives beyond psychiatry (eds P Statsny, P Lehmann): 146-60. Peter Lehmann Publishing.
2. Agar-Jacomb KM (2006) Mental Health Crisis Services. What Do Service Users Need When in Crisis? A Retrospective Study. University of Auckland.
3. Alanen YO, Lehtinen K, Räkköläinen V, et al (1991) Need-adapted treatment of new schizophrenic patients. Experiences and results of the Turku Project. Acta Psychiatrica Scandinavica; 83: 363-72.
4. Barnes M, Berke J (1971) Mary Barnes. Two Accounts of a Journey through Madness. MacGibbon and Kee.
5. Bennett MR, Hacker PMS (2003) Philosophical Foundations of Neuroscience. Blackwell.
6. Bentall RP, Morrison AP (2002) More harm than good. The case against using antipsychotic drugs to prevent severe mental illness. Journal of Mental Health; 11: 351-6.
7. Bola JR, Mosher LR (2002) Predicting drug-free treatment response in acute psychosis from the Soteria Project. Schizophrenia Bulletin; 28: 559-75.
8. Bola JR, Mosher LR (2003) Treatment of acute psychosis without neuroleptics. Two-year outcomes from the Soteria Project. Journal of Nervous and Mental Disease; 191: 219-29.
9. Bola JR (2006) Medication-free research in early episode schizophrenia. Evidence of long-term harm? Schizophrenia Bulletin; 32: 288-96.
10. JR Bola, Lehtinen, K, Cullberg, J, et al (2009) Psychosocial treatment, antipsychotic postponement, and low-dose medication strategies in first-episode psychosis: a review of the literature. Psychosis; 1: 4-18.
11. Burston D (2000) The Crucible of Experience: R.D. Laing and the Crisis of Psychotherapy. Harvard University Press.
12. Calton T, Ferriter M, Huband N, et al (2008) A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia. Schizophrenia Bulletin; 34: 181-92.
13. Calton T, Cheetham A, D'Silva K, et al (2009) International schizophrenia research and the concept of patient-centredness: an analysis over two decades. International Journal of Social Psychiatry; 55: 157-69.
14. Carpenter WT, McGlashan TH, Strauss JS (1977) The treatment of acute schizophrenia without drugs. An investigation of some current assumptions. American Journal of Psychiatry; 134: 14-20.
15. Carpenter WT (1997a) The risk of medication-free research. Schizophrenia Bulletin; 23: 11-8.
16. Carpenter WT, Schooler NR, Kane JM (1997b) The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry; 54: 401-7.
17. Ciompi L, Dauwalder HP, Maier C, et al (1992) The pilot project 'Soteria Berne'. Clinical experiences and results. British Journal of Psychiatry; 161 (suppl 18): 145-53.
18. Ciompi L, Hoffmann H (2004) Soteria Berne. An innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic. World Psychiatry; 3: 140-6.
19. Cooper D (1967) Psychiatry and Anti-psychiatry. Tavistock Press.
20. Cullberg J, Levander S, Holmqvist R, et al (2002) One-year outcome in first episode psychosis patients in the Swedish Parachute project. Acta Psychiatrica Scandinavica; 106: 276-85.
21. Cullberg J, Mattsson S, Levander R, et al (2006) Treatment costs and clinical outcomes for first episode schizophrenia patients. A 3-year follow-up of the Swedish 'Parachute Project' and two comparison groups. Acta Psychiatrica Scandinavica; 114: 274-81.
22. Davis JM (1976) Recent developments in the drug treatment of schizophrenia. American Journal of Psychiatry; 133: 208-14.
23. Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry; 60: 553-64.
24. Day J, Kinderman P, Bentall R (1997) A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica; 97: 93-7.
25. Department of Health (1999) National Service Framework for Mental Health. Department of Health.
26. Department of Health (2003) Building on the Best. Choice, Responsiveness and Equity in the NHS. Department of Health.
27. Department of Health (2008) High Quality Care for All. Department of Health.
28. Descartes R (1637) Discours de la méthode pour bien conduire sa raison, et chercher la verité dans les sciences. Reprinted (2006) as A Discourse on the Method (trans I Maclean). Oxford University Press.
29. Digby A (1985) Madness, Morality and Medicine. A Study of the York Retreat, 1796-1914. Cambridge University Press.
30. Endicott J, Spitzer RL, Fleiss JL, et al (1976) The Global Assessment Scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry; 33: 766-71.
31. Fins JJ, Miller FG (1997) The call of the sirens. Navigating the ethics of medication-free research in schizophrenia. Archives of General Psychiatry; 54: 415-6.
32. Fulford KWM (1996) Concepts of disease and the meaning of patient-centred care. In Essential Practice in Patient-centred Care (ed KWM Fulford, T Hope): 3-4. Blackwell Science.
33. General Medical Council (1998) Seeking Patients' Consent. The Ethical Considerations. General Medical Council.
34. Goldstein MJ, Rodnick EH, Evans JR, et al (1978) Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry; 35: 1169-77.
35. Goldstein JL, Godemont MML (2003) The legend and lessons of Geel, Belgium. A 1500-year-old legend, a 21st-century model. Community Mental Health Journal; 39: 441-58.
36. Gray P (2006) The Madness of Our Lives. Experiences of Mental Breakdown and Recovery. Jessica Kingsley.
37. Griesinger W (1868) Vorwort. Archiv für Psychiatrie und Nervenkrankheiten; 1: 3.
38. Grisso T, Appelbaum PS (1995) Comparison of standards for assessing patients' capacities to make treatment decisions. American Journal of Psychiatry; 152: 1033-7.
39. Harrow M, Grossman L, Jobe T, et al (2005) Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophrenia Bulletin; 31: 723-34.
40. Harrow M, Jobe TH (2007) Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications. A 15-year multifollow-up study. Journal of Nervous and Mental Disease; 195: 406-14.
41. Hennessy S, Bilker WB, Knauss JS, et al (2002) Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs. Cohort study using administrative data. BMJ; 325: 1070-2.
42. Hogarty GE, Goldberg SC, Schooler S, et al (1974) Drug and sociotherapy in the aftercare of schizophrenic patients II. Two year relapse rates. Archives of General Psychiatry; 31: 603-8.
43. Hope T (2002) Evidence-based patient choice and psychiatry. Evidence-Based Mental Health; 5: 100-1.
44. Hyman SE, Lieberman J, Weinberger DR (1998) Schizophrenia. Understanding It, Treating It, Living with It. Library of Congress.
45. Jones PB, Barnes TRE, Davies L, et al (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry; 63: 1079-87.
46. Kane J, Meltzer H, Carson W, et al (2007) Aripiprazole for treatment-resistant schizophrenia. Results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry; 68: 213-23.
47. Klein DF, Rosen B (1973) Premorbid asocial adjustment and response to phenothiazine treatment among schizophrenic inpatients. Archives of General Psychiatry; 29: 480-5.
48. Lehtinen V, Aaltonen J, Koffert T, et al (2000) Two-year outcome in first-episode psychosis treated according to an integrated model. Is immediate neuroleptisation always needed? European Psychiatry; 15: 312-20.
49. Lewis SW, Tarrier N, Drake, RJ (2005) Integrating non-drug treatments in early schizophrenia. British Journal of Psychiatry; 187: 65-71.
50. Lieberman JA, Scott Stroup, T, McEvoy, JP, et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine; 353: 1209-23.
51. Loebel AD, Lieberman JA, Alvir JM, et al (1992) Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry; 149: 1183-8.
52. May PRA, Tuma AH, Dixon WJ, et al (1981) Schizophrenia: a follow-up study of the results of five forms of treatment. Archives of General Psychiatry; 38: 776-84.
53. Moncrieff J, Crawford MJ (2001) British Psychiatry in the 20th century. Observations from a psychiatric journal. Social Science and Medicine; 53: 349-56.
54. Moncrieff J (2003) Clozapine v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. British Journal of Psychiatry; 183: 161-6.
55. Moser DJ, Reese RL, Schultz SK, et al (2005) Informed consent in medication-free schizophrenia research. American Journal of Psychiatry; 162: 1209-11.
56. Mosher LR, Reifman A, Menn, A (1973) Characteristics of non-professionals serving as primary therapists for acute schizophrenics. Hospital and Community Psychiatry; 24: 391-6.
57. Mosher LR, Menn A, Matthew SM (1975) Soteria. Evaluation of a home-based treatment for schizophrenia. American Journal of Orthopsychiatry; 45: 455-67.
58. Mosher LR (1999) Soteria and other alternatives to acute psychiatric hospitalization. A personal and professional review. Journal of Nervous and Mental Disease; 187: 142-9.
59. Mosher LR (2004a) Non-hospital, non-drug interventions with first-episode psychosis. In Models of Madness. Psychological, Social and Biological Approaches to Schizophrenia (eds J Read, LR Mosher, R Bentall): 349-64. Brunner-Routledge.
60. Mosher LR, Hendrix V (2004b) Soteria. Through Madness to Deliverance. XLibris.
61. National Institute for Clinical Excellence (2002) Clinical Guideline 1. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE.
62. Oehl M, Hummer M, Fleischhacker WW (2000) Compliance with antipsychotic treatment. Acta Psychiatrica Scandinavica; 102: 83-6.
63. Pasamanick B, Scarpetti FR, Dinitz S (1967) Schizophrenics in the Community. An Experimental Study in the Prevention of Rehospitalization. Appleton-Century-Crofts.
64. Pierloot RA, Demarsin M (1981) Family care versus hospital stay for chronic psychiatric patients. International Journal of Social Psychiatry; 27: 217-24.
65. Pincus HA, Henderson B, Blackwood D, et al (1993) Trends in research in two general psychiatric journals in 1969-1990. Research on research. American Journal of Psychiatry; 150: 135-42.
66. Podvoll EM (2003) Recovering Sanity. A Compassionate Approach to Understanding and Treating Psychosis. Shambhala.
67. Porter R (2002) Madness. A Brief History. Oxford University Press.
68. Pullen G (1999) Schizophrenia. Hospital communities for the severely disturbed. In Therapeutic Communities. Past, Present and Future (eds P Campling, R Haigh): 140-50. Jessica Kingsley.
69. Rappaport M, Hopkins HK, Hall K, et al (1978) Are there schizophrenics for whom drugs may be unnecessary or contraindicated? International Pharmacopsychiatry; 13: 100-11.
70. Read J, Mosher L, Bentall R (2004) Models of Madness. Psychological, Social and Biological Approaches to Schizophrenia. Brunner-Routledge.
71. Rogers A, Day JC, Williams B, et al (1998) The meaning and management of neuroleptic medication. A study of patients with a diagnosis of schizophrenia. Social Science and Medicine; 47: 1313-23.
72. Rose D (2006) Consciousness. Philsophical, Psychological, and Neural Theories. Oxford University Press.
73. Rothman KJ, Michels KB (1994) The continuing unethical use of placebo controls. New England Journal of Medicine; 331: 394-8.
74. Schooler NR, Goldberg SC, Boothe H, et al (1967) One year after discharge. Community adjustment of schizophrenic patients. American Journal of Psychiatry; 123: 986-95.
75. Seikkula J, Aaltonen J, Rasinkangas A, et al (2003) Open dialogue approach. Treatment principles and preliminary results of a two-year follow-up on first episode schizophrenia. Ethical and Human Sciences and Services; 5: 163-82.
76. Seikkula J, Aaltonen J, Alakare B, et al (2006) Five-year experience of first-episode nonaffective psychosis in open-dialogue approach. Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research; 16: 214-28.
77. Statsny P, Lehmann, P (2007) Alternatives Beyond Psychiatry. Peter Lehmann Publishing.
78. Warner R (1997) Recovery from Schizophrenia. Psychiatry and Political Economy. Routledge.
79. Watkins J (2006) Healing Schizophrenia. Using Medication Wisely. Michelle Anderson.
80. Wirt RD, Simon W (1959) Differential Treatment and Prognosis in Schizophrenia. Charles C Thomas.
81. Wyatt RJ (1997) Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophrenia Bulletin; 23: 3-9.
82. Zarate CA, Patel J (2001) Sudden cardiac death and antipsychotic drugs. Do we know enough? Archives of General Psychiatry; 58: 1168-71.